Ncc Group (OTCMKTS:NCCGF - Get Free Report) and Aurora Innovation (NASDAQ: AUR - Get Free Report) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Analyst Recommendations This is a summary of
Aurora Innovation, Inc. (AUR) Presents at 2nd Annual CG virtual Sustainability Summit Transcript
Aurora Innovation, Inc. (AUR) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Aurora Innovation: Too Slow To Commercialize
Aurora Innovation, Inc. (AUR) Q4 2025 Earnings Call Transcript
Aurora Innovation, Inc. (AUR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.11 per share a year ago.
Aurora (AUR) is upgraded to Buy with a $5.8 price target, reflecting 22% upside amid early commercialization momentum. AUR has robust $1.25B liquidity, and a narrowing net loss, supporting a 15+ month runway. Key 2026 catalysts include second-generation hardware (50% cost reduction) and the Detmar Logistics contract, validating scalability and technology maturity.
Aurora Innovation remains in a cautious crawl phase, with limited near-term revenue and slow scaling despite initial autonomous trucking lane launches. The autonomous trucking company targets only several hundred driverless trucks by end of 2026, while competitors like Kodiak AI and PlusAI are accelerating, eroding any first-mover advantage. Financials are challenging: $1M quarterly revenue, $9B market cap, significant cash burn, and ongoing share dilution to fund operations.
If the roadways are filled with self-driving trucks someday, then Aurora Innovation (NASDAQ:AUR) and its investors could be due for a financial windfall.
Aurora Innovation, Inc. (AUR) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.13 per share a year ago.
Aurinia Pharmaceuticals is rated BUY, driven by strong Lupkynis sales growth and a robust cash position supporting pipeline development. AUPH's Lupkynis leads as the first FDA-approved oral therapy for lupus nephritis, with 22% YoY revenue growth and expanding physician adoption. The company's pipeline drug, AUR200, targets dual immune proteins and offers long-term diversification potential in a multi-billion-dollar autoimmune market.
Aurora Innovation, Inc. (NASDAQ:AUR ) Evercore ISI's Autonomous, ADAS & AI Forum September 30, 2025 10:15 AM EDT Company Participants David Maday - Chief Financial Officer Conference Call Participants Chris McNally - Evercore ISI Institutional Equities, Research Division Presentation Chris McNally Evercore ISI Institutional Equities, Research Division Thanks so much for coming back. Chris McNally, Evercore ISI.